Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing a two-pronged strategy to address neurological health, focusing on its investigational multiple sclerosis therapy Lucid-MS and its proprietary dietary supplement unbuzzd. The company’s approach underscores the potential for innovative therapies to tackle challenging conditions, from autoimmune diseases to alcohol misuse disorders.
Lucid-MS is designed to target PAD2, an enzyme associated with myelin degradation in multiple sclerosis. Unlike conventional treatments that primarily modulate the immune system, Lucid-MS aims to protect and potentially restore the myelin sheath, which is crucial for nerve function. The company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 trial, and is supporting the development through an imaging collaboration with Massachusetts General Hospital. This strategy could offer a new avenue for patients who do not respond adequately to existing therapies.
In a separate initiative, Quantum BioPharma’s unbuzzd is designed to support alcohol metabolism and reduce acute intoxication and hangover effects. The company cites results from a randomized, placebo-controlled clinical trial demonstrating its efficacy. This product addresses the broader issue of alcohol misuse, which has significant social and health implications. By offering a supplement that mitigates the effects of alcohol, Quantum BioPharma is entering a market with substantial demand, particularly among individuals seeking to moderate their alcohol intake or recover more quickly from its effects.
The company has structured its unbuzzd business to maximize value. It spun out the over-the-counter version to Unbuzzd Wellness Inc. (UWI), led by industry veterans, while retaining a 19.84% ownership stake as of March 31, 2026. Quantum BioPharma also receives royalty payments of 7% of sales from unbuzzd until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. This arrangement allows Quantum BioPharma to benefit from the commercial success of unbuzzd while retaining 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
The company’s focus on both a prescription therapy and an over-the-counter supplement reflects a diversified portfolio approach. Lucid-MS, if approved, could address a significant unmet medical need in multiple sclerosis, a disease that affects millions worldwide. Meanwhile, unbuzzd taps into the growing wellness market, offering a practical solution for alcohol-related issues.
The implications of this dual strategy are considerable. For investors, Quantum BioPharma offers exposure to two distinct but complementary markets. The success of Lucid-MS in clinical trials could position the company as a leader in MS treatment, while unbuzzd provides a potential revenue stream that is not dependent on lengthy regulatory approval processes. For patients, the development of new therapies and supplements could offer hope for improved quality of life.
As Quantum BioPharma continues to advance its pipeline, it remains committed to addressing challenging neurodegenerative, metabolic, and alcohol misuse disorders. The company’s innovative approach, as highlighted in its recent announcements, demonstrates a forward-thinking mindset in the biopharmaceutical industry.
For more information, visit the company’s newsroom at https://ibn.fm/QNTM.
